NCT01244581

Brief Summary

The purpose of the study is to assess the efficacy of amoxicillin-clavulanate in treating acute otitis media in children. The primary end point is time to disappearance of middle ear effusion which monitored by daily tympanometry performed by families and study physicians.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
84

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Sep 1999

Longer than P75 for phase_3

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 1999

Completed
11.2 years until next milestone

First Submitted

Initial submission to the registry

November 18, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 19, 2010

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2012

Completed
Last Updated

June 20, 2012

Status Verified

June 1, 2012

Enrollment Period

12.8 years

First QC Date

November 18, 2010

Last Update Submit

June 19, 2012

Conditions

Keywords

middle ear effusionamoxicillin-clavulanatetympanometry

Outcome Measures

Primary Outcomes (1)

  • Time (days) to disappearance of middle ear effusion

    Disappearance of middle ear effusion is defined as the first day of receiving a normal tympanogram (A-curve) in tympanometry.

    Within 60 days

Secondary Outcomes (1)

  • Time (days) to disappearance of pain

    Within 60 days

Study Arms (2)

Amoxicillin-clavulanate

EXPERIMENTAL

Oral amoxicillin-clavulanate 40 mg/kg/day divided in two daily doses for 7 days

Drug: Amoxicillin-clavulanate

Placebo

PLACEBO COMPARATOR
Drug: Amoxicillin-clavulanateDrug: Placebo

Interventions

Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days

Also known as: Clavurion
Amoxicillin-clavulanatePlacebo

Placebo mixture in two daily doses for 7 days

Placebo

Eligibility Criteria

AgeUp to 16 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children with acute otitis media

You may not qualify if:

  • Amoxicillin allergy
  • Tympanic membrane perforation
  • Tympanostomy tubes (current)
  • Complication of acute otitis media such as mastoiditis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Department of Pediatrics, Oulu University Hospital

Oulu, 90014, Finland

Location

Lääkärikeskus Mehiläinen

Oulu, 90100, Finland

Location

Related Publications (1)

  • Tapiainen T, Kujala T, Renko M, Koivunen P, Kontiokari T, Kristo A, Pokka T, Alho OP, Uhari M. Effect of antimicrobial treatment of acute otitis media on the daily disappearance of middle ear effusion: a placebo-controlled trial. JAMA Pediatr. 2014 Jul;168(7):635-41. doi: 10.1001/jamapediatrics.2013.5311.

MeSH Terms

Conditions

Otitis Media, SuppurativeOtitis Media with Effusion

Interventions

Amoxicillin-Potassium Clavulanate Combination

Condition Hierarchy (Ancestors)

SuppurationInfectionsOtitis MediaOtitisEar DiseasesOtorhinolaryngologic Diseases

Intervention Hierarchy (Ancestors)

Clavulanic AcidClavulanic Acidsbeta-LactamsLactamsAmidesOrganic ChemicalsAmoxicillinAmpicillinPenicillin GPenicillinsSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsDrug CombinationsPharmaceutical Preparations

Study Officials

  • Matti Uhari, Professor

    University of Oulu

    STUDY DIRECTOR
  • Terhi Tapiainen, MD, PhD

    University of Oulu

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M.D., Ph.D.

Study Record Dates

First Submitted

November 18, 2010

First Posted

November 19, 2010

Study Start

September 1, 1999

Primary Completion

June 1, 2012

Study Completion

June 1, 2012

Last Updated

June 20, 2012

Record last verified: 2012-06

Locations